Niels Andreasen

Stockholm, AB, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 51 publications

Phase 1/2a Intravenous and Subcutaneous Oligomer-Specific Antibody KHK6640 in Mild to Moderate Alzheimer's Disease.

Phase 1/2a Intravenous and Subcutaneous Oligomer-Specific Antibody KHK6640 in Mild to Moderate Alzheimer's Disease.

Journal: The journal of prevention of Alzheimer's disease

Published: January 17, 2024

Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer's disease.

Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer's disease.

Journal: European journal of nuclear medicine and molecular imaging

Published: October 19, 2018

Association of IL1RAP-related genetic variation with cerebrospinal fluid concentration of Alzheimer-associated tau protein.

Association of IL1RAP-related genetic variation with cerebrospinal fluid concentration of Alzheimer-associated tau protein.

Journal: Scientific reports

Published: July 13, 2018

Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study.

Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study.

Journal: Alzheimer's research & therapy

Published: March 29, 2018

Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease.

Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease.

Journal: The New England journal of medicine

Published: January 25, 2018

Ponezumab in mild-to-moderate Alzheimer's disease: Randomized phase II PET-PIB study.

Ponezumab in mild-to-moderate Alzheimer's disease: Randomized phase II PET-PIB study.

Journal: Alzheimer's & dementia (New York, N. Y.)

Published: October 26, 2017

Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia.

Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

Published: August 15, 2016

Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment.

Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

Published: August 15, 2016

A Genetic Variant of the Sortilin 1 Gene is Associated with Reduced Risk of Alzheimer's Disease.

A Genetic Variant of the Sortilin 1 Gene is Associated with Reduced Risk of Alzheimer's Disease.

Journal: Journal of Alzheimer's disease : JAD

Published: July 10, 2016

Serum neurofilament light protein predicts clinical outcome in traumatic brain injury.

Serum neurofilament light protein predicts clinical outcome in traumatic brain injury.

Journal: Scientific reports

Published: July 01, 2016

Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer's disease and elderly controls after oral administration of sembragiline.

Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer's disease and elderly controls after oral administration of sembragiline.

Journal: European journal of nuclear medicine and molecular imaging

Published: April 01, 2016

Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics.

Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics.

Journal: Journal of Alzheimer's disease : JAD

Published: March 12, 2016

Showing 1-12 of 51

Last Updated: 09/26/2026